BOTHELL, WA--(Marketwire - 08/03/10) - NEAH Power Systems, Inc., (OTC.BB:NPWZ - News), www.neahpower.com, the Company developing fuel cell based renewable energy, announced today that it is collaborating with a major US Defense Supplier to explore development of unique power solutions for potential customers. The Defense Supplier is a technology and innovation leader specializing in defense, homeland security and other government markets throughout the world. With a history of innovation, the Defense Supplier provides state-of-the-art electronics, mission systems integration and other capabilities in the areas of sensing; effects; and command, control, communications and intelligence systems, as well as a broad range of mission support services.
"This is further validation of our technology, and we are honored and privileged to work with such an industry leader. The team at NEAH looks forward to providing patented, differentiated power solutions for defense, homeland security, and other applications," said Dr. Chris D'Couto, President and CEO of NEAH Power Systems.
"We produce a number of systems and components, which could potentially benefit from NEAH Power Systems' anaerobic fuel cell technology. We would like to work together to explore how NEAH Power Systems' technology may be applied to complement our solutions for enhanced operation of equipment for our customers," commented the Vice President of Advanced Technologies for the Defense Supplier.
About NEAH Power
NEAH Power Systems, Inc. (NPWZ) is developing long-lasting, efficient and safe power solutions for the military and for portable electronic devices and off the grid power solutions. NEAH uses a unique, patented, silicon-based design for its micro fuel cells that enable higher power densities, lower cost and compact form-factors.
Further company information can be found at www.neahpower.com.
Forward-Looking Statements
Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements," which are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. See NEAH Power System's Form 10-KSB for the fiscal year ended September 30, 2009 for a discussion of such risks, uncertainties and other factors. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
Thursday, August 5, 2010
Tuesday, August 3, 2010
mBeach Software Inc. Signs a Memorandum of Understanding in Emerging Russian and CIS Markets
TEL AVIV, Israel, Aug. 2, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced the signing of a memorandum of understanding (MOU) for the future distribution of SkinScan 650, the medical device for detection and diagnosis of skin cancer, signed by the wholly owned subsidiary, Skin Cancer Scanning Ltd. with a Russian Corp, active in the medical device field. This follows the company's recent announcement that it is targeting new market opportunities in this emerging region.
The new MOU covers the regulatory certification required by the Russian regulator, regional sales, marketing and distribution of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
"This MOU is an important element of our growth strategy for this region," said mBeach CEO Yossi Biderman. "Our product, though still a prototype, will be ideally suited, once the industrial prototype is approved by the Russian regulator, to meet the growing demand for better cancer detection. We are very excited at the potential of this market and see this MOU as a stepping stone to entering additional, attractive markets around the world."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The new MOU covers the regulatory certification required by the Russian regulator, regional sales, marketing and distribution of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
"This MOU is an important element of our growth strategy for this region," said mBeach CEO Yossi Biderman. "Our product, though still a prototype, will be ideally suited, once the industrial prototype is approved by the Russian regulator, to meet the growing demand for better cancer detection. We are very excited at the potential of this market and see this MOU as a stepping stone to entering additional, attractive markets around the world."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Amfil Technologies, Inc.(OTC.PK: AMFE) sole focus is the expert application and integration of its proprietary mPactTM and ozone technologies to clean
New Technology Anticipated to Generate Over One Million Dollars in Additional Revenue
SAN LUIS OBISPO, CA--(Marketwire - 08/02/10) - AMFIL Technologies, Inc. (Pinksheets:AMFE - News) integrator of ozone-based cleaning and antimicrobial systems for the food and beverage industry is pleased to announce they have completed the production and delivery of its new state-of-the-art, large capacity, fully automated, portable pilot mPact ozone cleaning and antimicrobial system. The system is capable of treating tanks, bottling lines, conveyers, floors and walls without the use of chemicals. Management estimates the technology will generate an additional one million dollars in revenue.
AMFIL Technologies, Inc. has already begun responding to multiple inquiries. Following final testing in Canada, the system will be relocated to the U.S. in order to meet the rising demand of the technology.
Ambrose Fillis, President and CEO of AMFIL Technologies, states, "The food and safety federal regulations in North America are requiring more stringent microbial control by meat processors, thereby requiring new technologies to fulfill these requirements. We are confident that our state-of-the-art mPact technology will meet and exceed these requirements. We are already experiencing increased inquiries for our technology. Once final testing of our technology is complete, we expect to immediately begin fulfilling orders."
For more information, please contact Investor Relations at (973) 351-3868 (973) 351-3868 or visit the company website directly: www.amfiltech.com.
About AMFIL Technologies, Inc.:
AMFIL is the manufacturer of cold water ozone-powered cleaning and antimicrobial systems for food/food processing equipment, zoological life support facilities/fish farming, and gaseous ozone fumigation systems for produce cold storage and transport. AMFIL's products include the mobile mPact-5 and mPact-10 systems, the mPact-25, mPact-45S, mPact-250S, and mPact-500S centralized systems, mPact-CSF cold storage fumigation system, and mPact-RCF refrigerated container fumigation system. In addition, AMFIL manufactures the mPact-CAS, a system designed specifically for cased meat log cleaning & antimicrobial treatment.
Safe Harbor
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
SAN LUIS OBISPO, CA--(Marketwire - 08/02/10) - AMFIL Technologies, Inc. (Pinksheets:AMFE - News) integrator of ozone-based cleaning and antimicrobial systems for the food and beverage industry is pleased to announce they have completed the production and delivery of its new state-of-the-art, large capacity, fully automated, portable pilot mPact ozone cleaning and antimicrobial system. The system is capable of treating tanks, bottling lines, conveyers, floors and walls without the use of chemicals. Management estimates the technology will generate an additional one million dollars in revenue.
AMFIL Technologies, Inc. has already begun responding to multiple inquiries. Following final testing in Canada, the system will be relocated to the U.S. in order to meet the rising demand of the technology.
Ambrose Fillis, President and CEO of AMFIL Technologies, states, "The food and safety federal regulations in North America are requiring more stringent microbial control by meat processors, thereby requiring new technologies to fulfill these requirements. We are confident that our state-of-the-art mPact technology will meet and exceed these requirements. We are already experiencing increased inquiries for our technology. Once final testing of our technology is complete, we expect to immediately begin fulfilling orders."
For more information, please contact Investor Relations at (973) 351-3868 (973) 351-3868 or visit the company website directly: www.amfiltech.com.
About AMFIL Technologies, Inc.:
AMFIL is the manufacturer of cold water ozone-powered cleaning and antimicrobial systems for food/food processing equipment, zoological life support facilities/fish farming, and gaseous ozone fumigation systems for produce cold storage and transport. AMFIL's products include the mobile mPact-5 and mPact-10 systems, the mPact-25, mPact-45S, mPact-250S, and mPact-500S centralized systems, mPact-CSF cold storage fumigation system, and mPact-RCF refrigerated container fumigation system. In addition, AMFIL manufactures the mPact-CAS, a system designed specifically for cased meat log cleaning & antimicrobial treatment.
Safe Harbor
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
Sunday, August 1, 2010
Mammoth Energy Group Signs First Letter of Intent to Acquire Lithium Concessions of Salt Gold Inter Chile Limitata of Chile
Mammoth Energy Group to Acquire 49% of Chilean Lithium Concessions at Salar de Maricunga
NEW YORK, NY--(Marketwire - 07/30/10) - Mammoth Energy Group Inc. (Pinksheets:MMTE - News) announced today that it has signed a Letter of Intent to acquire forty-nine percent (49%) of the outstanding stake of Salt Gold Inter Chile Limitata's concessions in the Salar de Maricunga located in the Atacama desert near Copiapo, Chile.
"We are very pleased to be making this first of many announcements on the official signing of the Letter of intent to acquire Salt Gold Inter Chile's lithium concessions," announced William Lieberman, President of Mammoth Energy Group. "This is the first of many strategic moves for Mammoth Energy Group," he added.
Salt Gold Inter Chile Limitata lithium concessions consist of 1008 acres in the Salar de Maricunga. Preliminary results of drilling and chemical analysis from its project under development has returned results and confirmed the presence of lithium -- potassium brine bearing aquifers. Brine Concentrations averaged grades of 650 ppm (parts per million) for lithium and 9500 ppm for potassium. These results confirm a significant third dimension to surface brines sampled on the project. The brine chemistry in the first test wells compares favorably to other Lithium companies in the region including the large multi-national Lithium producers whose estimates in the Atacama and throughout the region average 500 to 750 ppm Lithium and 9000-10000 ppm for potassium.
"Depths at the Salar de Maricunga average 100 Meters or 300 feet and currently acres are valued around $30,000 USD," said William Lieberman.
About Mammoth Energy Group Inc. (Pinksheets:MMTE - News) www.mammothenergygroup.com
Mammoth Energy Group Inc. is focused on acquiring, developing and operating strategic mining energy reserves in locations throughout the world. With an ever changing shift to alternative energy and fuels Mammoth Energy Group will be prepared to be a leading energy supplier and operator. Mammoth Energy's goal is to become an important partner as the world's energy paradigm begins to change throughout the next decade and beyond.
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; and other risks detailed in the Company's filings with the Securities and Exchange Commission.
These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.
NEW YORK, NY--(Marketwire - 07/30/10) - Mammoth Energy Group Inc. (Pinksheets:MMTE - News) announced today that it has signed a Letter of Intent to acquire forty-nine percent (49%) of the outstanding stake of Salt Gold Inter Chile Limitata's concessions in the Salar de Maricunga located in the Atacama desert near Copiapo, Chile.
"We are very pleased to be making this first of many announcements on the official signing of the Letter of intent to acquire Salt Gold Inter Chile's lithium concessions," announced William Lieberman, President of Mammoth Energy Group. "This is the first of many strategic moves for Mammoth Energy Group," he added.
Salt Gold Inter Chile Limitata lithium concessions consist of 1008 acres in the Salar de Maricunga. Preliminary results of drilling and chemical analysis from its project under development has returned results and confirmed the presence of lithium -- potassium brine bearing aquifers. Brine Concentrations averaged grades of 650 ppm (parts per million) for lithium and 9500 ppm for potassium. These results confirm a significant third dimension to surface brines sampled on the project. The brine chemistry in the first test wells compares favorably to other Lithium companies in the region including the large multi-national Lithium producers whose estimates in the Atacama and throughout the region average 500 to 750 ppm Lithium and 9000-10000 ppm for potassium.
"Depths at the Salar de Maricunga average 100 Meters or 300 feet and currently acres are valued around $30,000 USD," said William Lieberman.
About Mammoth Energy Group Inc. (Pinksheets:MMTE - News) www.mammothenergygroup.com
Mammoth Energy Group Inc. is focused on acquiring, developing and operating strategic mining energy reserves in locations throughout the world. With an ever changing shift to alternative energy and fuels Mammoth Energy Group will be prepared to be a leading energy supplier and operator. Mammoth Energy's goal is to become an important partner as the world's energy paradigm begins to change throughout the next decade and beyond.
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; and other risks detailed in the Company's filings with the Securities and Exchange Commission.
These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.
mBeach Software Inc. Targeting New International Market Opportunities
TEL AVIV, Israel, July 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States (CIS)
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
mBeach CEO Yossi Biderman commented, "One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
mBeach CEO Yossi Biderman commented, "One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
.AMFIL Technologies Announces Additional $150,000 Order From Southwest US Chili Pepper Processor
SAN LUIS OBISPO, CA--(Marketwire - 07/30/10) - AMFIL Technologies, Inc. (Pinksheets:AMFE - News), an integrator of ozone-based cleaning and antimicrobial systems for the food and beverage industry, is pleased to announce the sale of four multiple ozone cleaning and antimicrobial systems to Southwest US Chili Pepper Processor. This order generates an additional $150,000 in revenue.
The multiple ozone cleaning and antimicrobial systems reduce the amount of pathogenic microorganisms found on chili peppers grown in the US and imported from Mexico. This is accomplished by keeping both equipment and harvested chili products clean during operation. Unlike traditional chemical cleaners or sanitizers, AMFIL's mPact™ systems can treat both product and/or equipment concurrently during processing. The mPact™ systems are approved for use by the National Organic Program and requires no chemicals.
Ambrose Fillis, President and CEO of AMFIL Technologies, Inc. states, "The need for additional antimicrobial intervention points is important for chili processors in order to reduce potentially deadly pathogens that have recently plagued facilities within their industry. The unique ability to clean and antimicrobially treat products during processing has been very helpful and scientifically validated." Ambrose further stated, "Our microbial testing with normal customer based providers has shown significant reductions in microbial counts across the board. Both the dry and wet processing lines of peppers for our customers in the southwest have resulted in significant reductions in microbial counts. Our success has been due to both mPact™ mobile and stationary re-circulating systems to clean and antimicrobially treat food and processing equipment."
ABOUT AMFIL Technologies, Inc. - AMFIL is the manufacturer of cold water ozone cleaning and antimicrobial systems for food/food processing equipment, aquaculture, and gaseous ozone fumigation systems for produce cold storage and refrigerated produce transport containers. AMFIL's products include the mobile mPact-5 and mPact-10 systems, the mPact-25, mPact-45S, mPact-120S, mPact-250S, and mPact-500S centralized systems, mPact-CSF cold storage fumigation system, and mPact-RCF refrigerated container (reefer) fumigation system. In addition, AMFIL also offers the mPact-CAS, a system designed specifically for cased meat log cleaning & antimicrobial treatment. Please visit www.amfiltech.com for additional information on mPact™ systems.
Parties interested in obtaining further information or receiving news releases from AMFIL Technologies may e-mail a request to dcarpenter@amfiltech.com or visit AMFIL's corporate website at www.amfiltech.com.
Safe Harbor
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
The multiple ozone cleaning and antimicrobial systems reduce the amount of pathogenic microorganisms found on chili peppers grown in the US and imported from Mexico. This is accomplished by keeping both equipment and harvested chili products clean during operation. Unlike traditional chemical cleaners or sanitizers, AMFIL's mPact™ systems can treat both product and/or equipment concurrently during processing. The mPact™ systems are approved for use by the National Organic Program and requires no chemicals.
Ambrose Fillis, President and CEO of AMFIL Technologies, Inc. states, "The need for additional antimicrobial intervention points is important for chili processors in order to reduce potentially deadly pathogens that have recently plagued facilities within their industry. The unique ability to clean and antimicrobially treat products during processing has been very helpful and scientifically validated." Ambrose further stated, "Our microbial testing with normal customer based providers has shown significant reductions in microbial counts across the board. Both the dry and wet processing lines of peppers for our customers in the southwest have resulted in significant reductions in microbial counts. Our success has been due to both mPact™ mobile and stationary re-circulating systems to clean and antimicrobially treat food and processing equipment."
ABOUT AMFIL Technologies, Inc. - AMFIL is the manufacturer of cold water ozone cleaning and antimicrobial systems for food/food processing equipment, aquaculture, and gaseous ozone fumigation systems for produce cold storage and refrigerated produce transport containers. AMFIL's products include the mobile mPact-5 and mPact-10 systems, the mPact-25, mPact-45S, mPact-120S, mPact-250S, and mPact-500S centralized systems, mPact-CSF cold storage fumigation system, and mPact-RCF refrigerated container (reefer) fumigation system. In addition, AMFIL also offers the mPact-CAS, a system designed specifically for cased meat log cleaning & antimicrobial treatment. Please visit www.amfiltech.com for additional information on mPact™ systems.
Parties interested in obtaining further information or receiving news releases from AMFIL Technologies may e-mail a request to dcarpenter@amfiltech.com or visit AMFIL's corporate website at www.amfiltech.com.
Safe Harbor
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.
Wednesday, July 28, 2010
Mbeach Software Inc. Targeting Growing Market for Non-Intrusive Technologies to Detect Skin Cancer
TEL AVIV, Israel, July 19, 2010 (GLOBE NEWSWIRE) -- Mbeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.
Annual rates of skin cancer are increasing each year, representing a growing public concern. According to the American Academy of Dermatology (www.aad.org), more than two million cases of skin cancer are diagnosed in the United States each year. Recent research in the UK found the rate of men dying from the deadliest form of skin cancer has doubled over the past three decades. Current estimates are that one in five Americans will be diagnosed with skin cancer in their lifetime.
In the United States alone, the total direct cost associated with the treatment for non-melanoma skin cancer is estimated at $1.5 billion. The global market, including treatment for melanoma skin cancer, is estimated at several billion dollars.
Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. Another disadvantage with current diagnostic methods is that they usually rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue. Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.
SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Annual rates of skin cancer are increasing each year, representing a growing public concern. According to the American Academy of Dermatology (www.aad.org), more than two million cases of skin cancer are diagnosed in the United States each year. Recent research in the UK found the rate of men dying from the deadliest form of skin cancer has doubled over the past three decades. Current estimates are that one in five Americans will be diagnosed with skin cancer in their lifetime.
In the United States alone, the total direct cost associated with the treatment for non-melanoma skin cancer is estimated at $1.5 billion. The global market, including treatment for melanoma skin cancer, is estimated at several billion dollars.
Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. Another disadvantage with current diagnostic methods is that they usually rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue. Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.
SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Subscribe to:
Posts (Atom)